 |
|
Solving the drug price crisis
March 18, 2008The mounting U.S. drug price crisis can be contained and eventually reversed by separating drug discovery from drug marketing and by establishing a non-profit company to oversee funding for new medicines, according to two MIT experts on the pharmaceutical industry.
Stan Finkelstein, M.D., senior research scientist in MIT's Engineering Systems Division, and Peter Temin, Elisha Gray II Professor of Economics, present their research and detail their proposal in their new book, "Reasonable Rx: Solving the Drug Price Crisis," published by Financial Times Press.
Finkelstein and Temin address immediate national problems--the rising cost of available medicines, the high cost of innovation and the 'blockbuster' method of selecting drugs for development--and predict worsening new ones, unless bold steps are taken.
"Drug prices in the United States are higher than anywhere else in the world. Right now, the revenues from those drugs finance research and development of new drugs. We propose to reduce prices, not at the expense of innovation, but by changing the way innovation is financed," said Temin, also the author of "Taking Your Medicine: Drug Regulation in the US."
"Nationally, if we keep the current structure, in 50 years only hedge fund managers will be able to afford prescription drugs. Drug development will focus on therapies for those small groups of people who can pay a thousand dollars a pill. With income distribution widening and insurance carriers already refusing some coverage, this would be a disaster," said Temin.
"Prescription drugs have been left out of previous efforts to reform the delivery of health care. New initiatives to expand coverage must include a plan to reduce the high cost of drugs," Finkelstein added.
The book, which draws on the researchers' expertise in the realms of medicine and economics, proposes eliminating the linkage between drug prices and the cost of drug discovery while financing innovation and addressing the needs of society.
Their first bold step is conceptual, recognizing that we all have a critical stake in the products of pharmaceutical research.
Next, drawing on recent history, they propose dividing drug companies into drug discovery/development firms and drug marketing/distribution firms, just as electric utility firms were separated into generation and distribution companies in the 1990s.
Following the utility model, Finkelstein and Temin propose establishing an independent, public, non-profit Drug Development Corporation (DDC), which would act as an intermediary between the two new industry segments -- just as the electric grid acts as an intermediary between energy generators and distributors.
The DDC also would serve as a mechanism for prioritizing drugs for development, noted Finkelstein.
"It is a two-level program in which scientists and other experts would recommend to decision-makers which kinds of drugs to fund the most. This would insulate development decisions from the political winds," he said.
Finkelstein and Temin's plan would also insulate drug development from the blockbuster mentality, which drives companies to invest in discovering a billion-dollar drug to offset their costs.
An example of the blockbuster mentality is developing a new drug for hypertension, one that varies only slightly from those already on the market, but that can bring in huge profits if aggressively marketed.
For Finkelstein, a physician, and Temin, an economist, societal needs for medicines are swiftly extending beyond national boundaries: Diseases affecting the developing world--afflicting people too poor to make drug development attractive for businesses--will soon affect health inside the United States.
"Global travel and climate change both require that U.S. drug development and innovation policy rethink the way drugs are developed, and for whom. Air travel, migrations, a global workforce--all these mean unusual diseases could become usual here," Temin noted.
Climate change also may affect drugs their proposed DDC would select for funding.
"Especially in the southern states, tropical diseases are likely to increase with global warming, and people will need treatments for them. In our plan, the DDC would encourage research in advance of the market - and, we hope, in advance of disaster," he said.
Massachusetts Institute of Technology
"Drug prices in the United States are higher than anywhere else in the world. Right now, the revenues from those drugs finance research and development of new drugs. We propose to reduce prices, not at the expense of innovation, but by changing the way innovation is financed," said Temin, also the author of "Taking Your Medicine: Drug Regulation in the US."
"Nationally, if we keep the current structure, in 50 years only hedge fund managers will be able to afford prescription drugs. Drug development will focus on therapies for those small groups of people who can pay a thousand dollars a pill. With income distribution widening and insurance carriers already refusing some coverage, this would be a disaster," said Temin.
"Prescription drugs have been left out of previous efforts to reform the delivery of health care. New initiatives to expand coverage must include a plan to reduce the high cost of drugs," Finkelstein added.
The book, which draws on the researchers' expertise in the realms of medicine and economics, proposes eliminating the linkage between drug prices and the cost of drug discovery while financing innovation and addressing the needs of society.
Their first bold step is conceptual, recognizing that we all have a critical stake in the products of pharmaceutical research.
Next, drawing on recent history, they propose dividing drug companies into drug discovery/development firms and drug marketing/distribution firms, just as electric utility firms were separated into generation and distribution companies in the 1990s.
Following the utility model, Finkelstein and Temin propose establishing an independent, public, non-profit Drug Development Corporation (DDC), which would act as an intermediary between the two new industry segments -- just as the electric grid acts as an intermediary between energy generators and distributors.
The DDC also would serve as a mechanism for prioritizing drugs for development, noted Finkelstein.
"It is a two-level program in which scientists and other experts would recommend to decision-makers which kinds of drugs to fund the most. This would insulate development decisions from the political winds," he said.
Finkelstein and Temin's plan would also insulate drug development from the blockbuster mentality, which drives companies to invest in discovering a billion-dollar drug to offset their costs.
An example of the blockbuster mentality is developing a new drug for hypertension, one that varies only slightly from those already on the market, but that can bring in huge profits if aggressively marketed.
For Finkelstein, a physician, and Temin, an economist, societal needs for medicines are swiftly extending beyond national boundaries: Diseases affecting the developing world--afflicting people too poor to make drug development attractive for businesses--will soon affect health inside the United States.
"Global travel and climate change both require that U.S. drug development and innovation policy rethink the way drugs are developed, and for whom. Air travel, migrations, a global workforce--all these mean unusual diseases could become usual here," Temin noted.
Climate change also may affect drugs their proposed DDC would select for funding.
"Especially in the southern states, tropical diseases are likely to increase with global warming, and people will need treatments for them. In our plan, the DDC would encourage research in advance of the market - and, we hope, in advance of disaster," he said.
Massachusetts Institute of Technology
Can healthcare systems afford Herceptin for early breast cancer?
New research into the cost of using the breast cancer drug Herceptin warns that healthcare authorities and the organisations advising them should not rush to prescribe it for early breast cancer without working out extremely carefully the budget implications and cost-effectiveness of the drug.
More Drug Price News Articles
 | Broken by William Cope Moyers From rock bottom to recovery—the son of veteran broadcaster Bill Moyers chronicles his life- shattering battle with addiction and the hard-won fight for recovery William Cope Moyers has come a long, long way. In 1994, he lay on the floor of an Atlanta crack house. His father had put together a search party. His worried family waited at home where Moyers had left them when he embarked on yet... |
 | My Friend Leonard by James Frey In the bold and heartbreaking My Friend Leonard, James Frey picks up the story of his extraordinary life pretty much where things left off in his breakout bestseller and Amazon.com Best Book of 2003, A Million Little Pieces, the fierce, in-your-face memoir about Frey's kamikaze run of self-destruction and his days in rehab. Fresh from a stint in jail from pre-rehab-related charges ("On my first... |
 | The Truth About the Drug Companies: How They Deceive Us and What to Do About It by Marcia Angell Many Americans have wondered why prescription drugs have become so expensive while advertising for those drugs seems to grow exponentially. Former New England Journal of Medicine Editor Marcia Angell has some answers. The pharmaceutical industry, according to Angell, is fraught with corruption and doing a disservice to customers, the federal government, and to the medical establishment itself. In... |
 | Random Family: Love, Drugs, Trouble, and Coming of Age in the Bronx by Adrian Nicole LeBlanc Random Family tells the American outlaw saga lurking behind the headlines of gangsta glamour, gold-drenched drug dealers, and street-corner society. With an immediacy made possible only after ten years of reporting, Adrian Nicole LeBlanc immerses the reader in the mind-boggling intricacies of the little-known ghetto world. She charts the tumultuous cycle of the generations, as girls become... |
 | Positively False: The Real Story of How I Won the Tour de France by Floyd Landis |
 | Outrage: How Illegal Immigration, the United Nations, Congressional Ripoffs, Student Loan Overcharges, Tobacco Companies, Trade Protection, and Drug Companies Are Ripping Us Off . . . And by Dick Morris, Eileen Mcgann Half of all illegal immigrants came into this country legally—and we have no way of knowing they're still here! Congressmen are putting their wives on their campaign payrolls—so that campaign contributions are really personal bribes! The ACLU won't allow its own directors free speech. Liberals want to strip us of the tools to stop terrorism. The UN is a cover for massive... |
 | The High Blood Pressure Hoax by Sherry A. Rogers Blood pressure drugs guarantee you will get worse, for they actually deplete the nutrients that cause high blood pressure, making sure you will need even more medications. They also shrink the brain and raise your risk of heart attack, senility and blindness. High blood pressure is not a deficiency of blood pressure-lowering drugs. But there are dozens of ways you can permanently cure your high... |
 | Your Drug May Be Your Problem: How and Why to Stop Taking Psychiatric Drugs by Peter R. Breggin, David Cohen Psychiatric drugs are prescribed to more than 20 million Americans. This book aims to convince us to stop taking these drugs, and to show us how to do it safely. The authors contend that after 15 minutes with a physician or psychiatrist, Americans are prescribed medications that we may take for years or a lifetime, which can do more harm than good. We're irritable, anxious, emotionally numbed,... |
 | Cooked: From the Streets to the Stove, from Cocaine to Foie Gras by Jeff Henderson |
 | The Cholesterol Hoax by Sherry A. Rogers Cholesterol is not the biggest cause of heart disease nor is it predictive of heart disease. In fact, over half the folks who die of a heart attack never had high cholesterol. But they did have other warnings that could have saved their lives, had they been checked. And the cure for these is spelled out here via safe non-prescription nutrients. Cholesterol is merely the messenger, the smoke... |
| © 2008 BrightSurf.com |